Completion of Privatization of Ondine

 
TIDMOBP 
 
Completion of Privatization of Ondine 
FOR:  ONDINE BIOMEDICAL INC. 
 
TSX, AIM SYMBOL:  OBP 
 
September 6, 2011 
 
Completion of Privatization of Ondine 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 6, 2011) - Ondine Biomedical Inc. (the "Company" or "Ondine") 
(TSX:OBP)(AIM:OBP) announced the completion today of the previously announced plan of arrangement (the 
"Arrangement") pursuant to which 0902337 B.C. Ltd., a private company whose sole shareholder is Carolyn Cross, 
Chairman and Chief Executive Officer of Ondine, has acquire all of the issued and outstanding common shares of 
Ondine. Under the Arrangement, the shareholders of Ondine immediately prior to the effective time of the 
Arrangement (the "Former Shareholders") are entitled to receive consideration of $0.33 per common share (the 
"Consideration") for each common share of Ondine previously owned by such Former Shareholder. Pursuant to the 
Arrangement, holders of options and warrants of Ondine immediately prior to the effective time of the 
Arrangement are entitled to receive $0.001 for each such security held and the options and warrants are now 
deemed to have been surrendered and cancelled. 
 
Any questions or requests for assistance in surrendering Ondine share certificates in order to receive the 
Consideration may be directed to the office of the depositary, Computershare Trust Company of Canada, Corporate 
Actions, toll free at 1 [phone] or by email at [e-mail]. Former Shareholders 
who were not a registered shareholder should contact their broker or other intermediary for details concerning 
receipt of the Consideration owing to such Former Shareholder. 
 
Cancellation of the admission to trading of the common shares of the Company on the AIM market of London Stock 
Exchange will occur at 7:00a.m. (London time) on September 7, 2011. 
 
Delisting of the common shares of the Company from the Toronto Stock Exchange is expected to occur shortly. In 
addition, the Company will apply to all applicable Canadian securities regulatory authorities in order to cease 
to be a reporting issuer. 
 
Pursuant to the terms of the Arrangement, Colin Watt, Michael Crane and Margaret Shaw have resigned as 
directors of the Company effective September 6, 2011. Ondine appreciates the contributions these directors made 
to the Company during their many years of service and wishes them every success in their future endeavors. 
 
Carolyn Cross, indirectly through the Purchaser now holds 9,661,468 Common Shares (including the 810,500 Common 
Shares previously beneficially held directly and indirectly by her, 183,151 Common Shares previously owned by 
an associate of hers and 591,090 Common Shares previously owned by the Courthill Foundation, a charitable 
foundation in which Ms. Cross is a director), which represents 100% of the issued and outstanding Common 
Shares. 
 
Carolyn Cross and the Purchaser will file an early warning report describing the Arrangement with applicable 
securities regulators, copies of which will be available under the Ondine profile at www.SEDAR.com. A copy of 
the report may be obtained from Carolyn Cross. The Purchaser's address is Suite 1560, One Bentall Centre, 505 
Burrard Street, Vancouver, British Columbia. 
 
About Ondine Biomedical Inc. 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and 
viral infections. The Company is focused on developing leading edge products utilizing its patented light- 
activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection 
provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic 
resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development 
laboratory in Bothell, Washington, USA. For additional information, please visit the Company's website at: 
www.ondinebio.com. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", "expect", 
"would" and other similar expressions, are forward-looking statements that involve a number of risks and 
uncertainties. The forward-looking statements contained in this release reflect the current views of Ondine 
with respect to future events and are necessarily based upon a number of assumptions and estimates that, while 
considered reasonable by Ondine, are inherently subject to various risks and uncertainties. Many factors, both 
known and unknown, could cause actual results, performance or achievements to be materially different from the 
results, performance or achievements that are or may be expressed or implied by such forward-looking 
information contained in this news release and Ondine has made assumptions based on or related to many of these 
factors. Such factors that could cause actual results to differ materially from those projected in the 
Company's forward-looking statements include, without limitation, the following: litigation, fluctuations in 
economic and equity market conditions, market acceptance of our technologies and products; our ability to 
obtain financing; our financial and technical resources relative to those of our competitors; our ability to 
keep up with rapid technological change; government regulation of our technologies; our ability to enforce our 
intellectual property rights and protect our proprietary technologies; the ability to obtain and develop 
partnership opportunities; the timing of commercial product launches; the ability to achieve key technical 
milestones in key products and other risk factors identified from time to time in the Company's public filings. 
Investors are cautioned against attributing undue certainty or reliance on forward-looking information. 
Although Ondine has attempted to identify important factors that could cause actual results to differ 
materially, there may be other factors that cause results not to be as anticipated, estimated, described or 
intended. Ondine does not intend, and does not assume any obligation, to update this forward-looking 
information to reflect changes in assumptions or changes in circumstances or any other events affecting such 
information, other than as required by applicable law. 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biomedical Inc. 
Carolyn Cross 
Chairman and CEO 
[phone] 
[e-mail] 
www.ondinebio.com 
 
OR 
 
Canaccord Genuity Limited 
Nominated Adviser 
Mark Williams/Bhavesh Patel 
[phone] 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this 
release. 
 
 
 
Ondine Biomedical Inc.